The concept of purinergic signalling arose from experiments designed to find the identity of the non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter in the gut. 1 However, it has taken many years for the more general importance of the various roles of ATP as a physiological messenger in the gut to be recognised. Later, after the concept of cotransmission was established, ATP, nitric oxide and vasoactive intestinal polypeptide were recognised as co-transmitters in NANC nerves, although the proportions vary in different gut regions. Following cloning experiments in the early 1990s, four subtypes of P1 (adenosine) receptors, seven subtypes of P2X ion channel receptors and eight subtypes of P2Y G-proteincoupled receptors have been recognised. 2 Many of these purinoceptor subtypes have been identified on the myenteric, submucosal motor, sensory and interneurons involved in synaptic neurotransmission and neuromodulation, and reflex activity of several kinds, including ascending excitatory and descending inhibitory reflex pathways (see fig 1) . Nucleotide receptors have also been shown to be expressed on enteric glial cells and interstitial cells of Cajal. Purinergic mechanosensory transduction, involving release of ATP from mucosal epithelial cells during distension to stimulate subepithelial nerve endings of intrinsic and extrinsic sensory nerves to modulate peristalsis and initiate nociception, respectively, is attracting current attention. 3 While most studies of purinergic signalling in the gut have been carried out in animal models, purinergic synaptic transmission has also been described in the human enteric nervous system. 4 Xu and colleagues have carried out an original and interesting study in a growth area of considerable current interest (see page 1230). While purinergic nociceptive signalling in a rat model of colitis has been studied where 30% trinitrobenzenesulfonic acid was administered by intrarectal enema, 6 this is the first time that the role of P2X receptor signalling has been studied with a rat model of irritable bowel syndrome (IBS)-like visceral hyperalgesia, using acetic acid (AA) infusion into the colon. The authors have shown that visceral hypersensitivity in their model is reversed by 29,39-O-(2,4,6-trinitrophenyl)-ATP, a
Correspondence to: Professor Geoffrey Burnstock, Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK; g.burnstock@ucl.ac.uk Figure 1 Schematic showing the localisation of receptors of purines and pyrimidines on neurons and non-neuronal effector cells in the gut, although some of the interacting pathways are not yet known. Extrinsic vagal and sacral parasympathetic nerves connect with non-adrenergic, noncholinergic (NANC) inhibitory neurons in the myenteric plexus expressing P2X 2 , P2X 3 , P2Y 1 , P2Y 6 and A 2B receptors, as well as with cholinergic motor neurons; these neurons are also activated by descending interneurons. Extrinsic sympathetic nerves modulate motility via excitatory motor neurons and constrict blood vessels in the gut via P2X 1 receptors. Extrinsic sensory nerves arising from cell bodies in dorsal root ganglia and with subepithelial terminals mediate nociception. Intrinsic sensory neurons in both myenteric and submucosal plexuses express P2X 2 and P2X 3 receptors, while a subpopulation also express P2Y 12 receptors; they connect with motor pathways involved in peristalsis. Excitatory motor neurons express P2X 2 , P2X 3 , P2X 2/3 , P2X 5 14 15 The involvement of purinergic signalling in other gut disorders is also being explored, 3 16 including: oesophageal reflux and swallowing, 17 diabetes, postoperative ileus, ischaemia, 18 Hirschsprung's disease 19 and Chaga's disease. A recent report has shown that intraduodenal administration of ATP concomitantly with ingestion of non-steriodal anti-inflammatory drugs attenuates the indomethacin-induced increase in small intestinal permeability in healthy humans and may indicate that ATP will be of benefit in the treatment of intestinal disorders in which intestinal permeability changes are involved. 20 Although it has taken a long time, it is now clear that purines and pyrimidines play pivotal roles in a variety of physiological activities in the gastrointestinal tract of mammals, including man. The most recent work has focused on the pathophysiological roles of purinergic signalling in the gut, and I believe that the time is ripe for serious exploration of the therapeutic potential of purinergic compounds for a variety of gut disorders. While there are some studies of perinatal development of purinergic signalling in the mammalian gut, I believe that further studies should be encouraged, particularly concerning purinergic signalling in enteric stem cells involved in development and regeneration, with implications in paediatric and geriatric medicine.
Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?
Charles N Bernstein
While it is generally agreed that screening for colon cancer is a rational strategy in chronic colitis of ulcerative colitis or Crohn's disease, there remains some debate over the approach to managing outcomes of dysplasia surveillance colonoscopy. While some have advocated for colectomy for low grade dysplasia, [1] [2] [3] others have argued for more surveillance; 4 while some have argued for polypectomy for adenoma-like masses (ALMs) 5 others have shown the potential for disasterous outcomes if polypectomy is pursued where rigorous follow-up will not be sustained. 6 However, there has been less discussion about the technical approach to dysplasia surveillance. In survey studies in the US and UK it was shown that surveillance colonoscopy frequency and biopsy protocols have varied widely. 7 8 One study suggested that at least 33 biopsies were required to maximise dysplasia discovery, 9 but this has never been revisited. To counter the problem of time and expense incurred with 30+ biopsies chromoendoscopy emerged as a means to target biopsies and otherwise minimise random multiple biopsies. 10 11 In this issue of Gut, Lutgens et al (see page 1246) address the very basic question of timing the initiation of dysplasia surveillance. 12 Elsewhere, it has been identified that colon cancers may occur before 8 years of disease. 13 14 However, in a countrywide 
